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1078–5884/00Assessing the Validity and Responsiveness
of Disease-specific Quality of Life Instruments
in Intermittent Claudication
T. Mehta,* A. Venkata Subramaniam, I. Chetter and P. McCollumAcademic Vascular Unit, Hull Royal Infirmary, Hull, UKPurpose. To recommend a suitable disease-specific quality of life (QOL) instrument for use in intermittent claudication (IC)
based on validity and responsiveness.
Methods. Seventy claudicants completed two generic (SF36 and EUROQOL) and three disease-specific (CLAUS,
VASCUQOL and SIPIC) QOL instruments prior to and 6 months after treatment (angioplasty or conservative therapy).
Ankle brachial pressure indices and treadmill walking distances were measured at each assessment and International Society
of Cardiovascular Surgery (ISCVS) recommended outcome measures were used to stratify the results. Construct and
convergent-divergent validity was assessed for the three disease-specific QOL instruments. Responsiveness was assessed
using effect sizes (effect size O0.5 is clinically significant).
Results. All clinical indicators improved significantly following treatment. All five domains of CLAUS, the VASCUQOL
and SIPIC showed highly significant spearman correlation with intermittent claudication distance (ICD) and maximum
walking distance (MWD) (0.267–0.697, pZ0.01), suggesting good construct validity. There was greater correlation
between like domains of CLAUS and SF36 than non-like domains suggesting good convergent-divergent validity. Pain
domain of CLAUS and VASCUQOL could detect mild clinical improvement significantly (effect sizes 0.55 and 0.67). Pain
and everyday life domain of CLAUS and the VASCUQOL could detect moderate clinical improvement significantly (effect
sizes 0.7, 0.74 and 0.56, respectively).
Conclusion. The three disease-specific QOL instruments (CLAUS, VASCUQOL, SIPIC) showed a high degree of construct
and convergent-divergent validity. Amongst the three disease-specific QOL instruments, the VASCUQOL was most
responsive and we would recommend its use in clinical practice.Keywords: Disease-specific quality of life; Intermittent claudication; Validity and responsiveness.Introduction
Intermittent claudication (IC) is a common condition,1
which significantly impairs quality of life (QOL).
Claudicants are limited not only in their walking
capacity and physical activity, but also demonstrate
substantial impairment in other QOL domains includ-
ing social functioning, emotional and mental health.2
Conservative management, exercise therapy, interven-
tional radiology and surgery have all been used in the
treatment of IC with the primary aim of reversing this
QOL impairment. However, the most appropriate
method of QOL analysis is disputed.
QOL may be analyzed using generic or disease-
specific instruments, with the later being more able toing author. Tapan Mehta, FRCS, Clinical Research
emic Vascular Unit, Hull Royal Infirmary, Anlaby
U3 2JZ, UK.
: tapanmehta99@yahoo.com
0046 + 07 $35.00/0 q 2005 Elsevier Ltd. All rights reserdetect small changes. The aim of this study was to
assess the validity and responsiveness of three
commonly utilised disease-specific QOL instruments
for IC, and make recommendations regarding stan-
dardisation of disease-specific QOL analysis in these
patients.Methods
A prospective study was conducted following ethics
committee approval. Seventy ISCVS category II
claudicants (38 men, median age 70 years) with life-
style limiting claudication were recruited into the
study over 1 year. Twenty-seven patients were current
smokers (38%) and 14 were diabetics (20%). Thirty
patients had bilateral claudication symptoms and in
these patients the more symptomatic side or with
equal symptoms, the side with the lower ankleEur J Vasc Endovasc Surg 31, 46–52 (2006)
doi:10.1016/j.ejvs.2005.08.028, available online at http://www.sciencedirect.com onved.
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analysis. Forty-seven patients underwent percuta-
neous transluminal angioplasty (PTA) and 23 patients
had conservative medical therapy (CMT). Patients
were assessed prior to treatment and at 6 months after
treatment. At each assessment patients’ clinical
indicators of lower limb ischaemia and QOL (generic
and disease-specific) were analysed. Two generic
questionnaires and three disease-specific question-
naires were used to analyse QOL. To achieve
completion of questionnaires and avoid automatic
patient responses, the order in which the question-
naires were presented to patients was varied and the
questionnaires were checked for omission following
self-completion by the patients.Clinical indicators of lower limb ischaemia
The clinical indicators of lower limb ischaemia
included were ankle brachial pressure index at rest
(ABPI-R) and post-exercise (ABPI-PE) and walking
distances—intermittent claudication distance (ICD)
and maximum walking distance (MWD)—using a
standard treadmill test (10 degree inclination at a
constant speed of 2.5 km/h). The patients had no
treadmill training prior to walking distance measure-
ment. Since, this policy was followed throughout the
study and for all patients, any effect of training (or lack
of) should be uniform across the study. The outcome
following treatment was also assessed using the
International Society of Cardio Vascular Surgery
(ISCVS) suggested outcome criteria (Table 1).Generic QOL instruments
Generic instruments included were the SF36 and the
EUROQOL. The SF36 has 36 items or questions and
records QOL over eight distinct dimensions or
domains—physical function, role physical, bodily
pain, general health, vitality, social function, role
emotional and mental health.3 The highest score for
each domain is 100 (best QOL) and the lowest score is 0
(worst QOL). The SF36 is a popular and widely used
QOL instruments in patients with peripheral vascularTable 1. ISCVS outcome criteria
C3 Markedly improved No ischaemic sy
C2 Moderately improved Improved by at
C1 Minimally improved ABPI improved
0 No change No categorical s
K1 Mildly worse ABPI decrease b
K2 Moderately worse One category w
K3 Markedly worse More than one cdisease. The EUROQOL is administered in two parts.
The first is a simple generic measure consisting of five
questions, each with three possible responses. This
part of the questionnaire is used to describe a brief
health profile over five dimensions: mobility, self-care,
usual activities, pain/discomfort and anxiety-
depression. The responses are also analysed using a
time trade off (TTO) matrix to calculate a single health
index called TTO index. The second part of the
EUROQOL is a visual rating scale from 0 (worst
imaginable health state) to 100 (best imaginable health
state). This is read off directly as the visual analogue
score (VAS). The EUROQOL thus produces a brief
health profile and two health indices the TTO index
and the VAS index.4Disease-specific QOL instruments
Disease-specific QOL instruments included were the
claudication scale (CLAUS), the Kings College Vas-
cular Quality of Life questionnaire (VASCUQOL) and
sickness impact profile-intermittent claudication
(SIPIC). The CLAUS is one of the earliest disease-
specific QOL instruments for IC. It originated in
Germany and has undergone several changes over
time.5,6 Currently, it consists of 47 questions that
produce a QOL health profile over five domains—
everyday life (EDL), pain (P), social living (SL), illness
specific fears (ISF) and psychological well-being (PW).
Each domain has a maximum score of 100 (best QOL)
and a minimum score of 0 (worst QOL).7 The
VASCUQOL was devised at the Kings College in
London and is a disease-specific QOL instrument
valid for use across the whole spectrum of patients
with peripheral vascular disease i.e. claudicants and
patients with critical ischaemia. It comprises of 25
questions each with seven possible responses. The
total VASCUQOL score is the average score of
questions answered and ranges from 1 (worst QOL)
to 7 (best QOL).8 The SIPIC was derived from the
generic questionnaire sickness impact profile (SIP) that
assesses sickness related behaviour.9 It is a simple
instrument that consists of 12 items and the SIPIC score
is simply the total number of dysfunctional items
endorsed. If none of the items are endorsed, the scoremptoms, any foot lesions healed, ABPI ‘normalised’ (O0.90)
least 1 category and ABPI improved by O0.10
by O0.10 but no categorical improvement or vice versa
hift and !0.10 change in ABPI
y O0.10 but no categorical deterioration or vice versa
orse or unexpected minor amputation
ategory worse or unexpected major amputation
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T. Mehta et al.48is 0 and this represents the best QOL. Conversely an
SIPIC of 12 represents worst QOL.
10Validity
‘Construct’ validity refers to the ability of the
instrument to confirm a hypothesis i.e. patients with
disease have significantly worse QOL than normal
persons. A high degree of construct validity is
suggested by a high correlation between QOL and
clinical indicators. ‘Convergent’ and ‘divergent’ val-
idity assess the correlation between like and non-like
domains amongst different QOL instruments.11Responsiveness
The responsiveness of a QOL instrument can be
analysed in several ways, but a widely accepted
method is using ‘effect sizes’.12 Effect sizes are defined
as the mean change found in a variable divided by the
standard deviation of that variable. Effect sizes are
used to translate the ‘before and after’ changes into a
standard unit of measurement that should provide a
clearer understanding of health status results. Effect
sizes can supplement standard statistical testing to
give a more complete and clinically relevant picture of
health status change.13 Effect size is the difference of
the median value post and pre treatment divided by
the inter-quartile range (IQR) of the pre-treatment
data. An effect size O0.5 is considered clinically
relevant.Statistical analysis
Data was collected and analysed using the statistical
package SPSS. Where possible, results are quoted
using median and inter-quartile range (IQR). Validity
of the QOL instruments was tested using Spearman
rank correlation test. When testing pre and postTable 2. Clinical outcome measures pre- and post-treatment (nZ70)
Parameter Pre-treatment
ICD, median (IQR)/m 34.1 (24.2–57.8)
MWD, median (IQR)/m 80.0 (54.4–124.8)
Resting ABPI (symptomatic side) 0.76 (0.61–0.90)
Post-exercise ABPI (symptomatic side) 0.55 (0.44–0.72)
ISCVS outcome criteria
K1 (mild deterioration)
0 (no change)
C1 (mild improvement)
C2 (moderate improvement)
Eur J Vasc Endovasc Surg Vol 31, 1 2006treatment results, the Wilcoxon matched pair test
was used.ResultsClinical indicators of lower limb ischaemia
All patients completed the study and there were no
dropouts. The pre-treatment median ICD was 34.1
metres (IQR 24.2–57.8 m) and pre-treatment median
MWD was 80.0 m (IQR 54.4–124.8 m). The pre-
treatment median resting and post-exercise ABPI on
the symptomatic side were 0.76 (IQR 0.61–0.90) and
0.55 (IQR 0.44–0.72), respectively. Following treatment,
there was a significant improvement in all clinical
parameters (p!0.001, Wilcoxon matched pair test).
The median increase in ICD and MWD was 42.4 m
(IQR 16.9–129.6 m) and 45.2 m (IQR 0–161.8 m),
respectively. The median increase in resting ABPI on
the symptomatic side was 0.11 (IQR 0–0.22).
According to the ISCVS outcome criteria, six
patients had mild deterioration (K1), 16 patients had
no change (0), 34 patients had mild improvement (C1)
and 14 patients had moderate improvement (C2).
Table 2 details the clinical outcome measures pre- and
post-treatment.Generic QOL instruments
According to the ISCVS outcome criteria, 48 of the 70
claudicants (69%) improved following treatment.
However, only four of the eight SF36 domains
significantly improved and these were the domains
of physical function, bodily pain, vitality and mental
health (p!0.05, Wilcoxon matched pair test). For the
EUROQOL, the TTO index improved significantly
after treatment from a median pre-treatment score of
0.66 to a median post-treatment score of 0.69 (pZ0.02Post-treatment Wilcoxon matched pair
test, p
89.3 (56.2–300.0) !0.001
138.3 (90.1–300.0) !0.001
0.91 (0.76–1.00) !0.001
0.70 (0.48–0.88) !0.001
6 patients
16 patients
34 patients
14 patients
Table 3. Quality of life measures pre and post treatment (nZ70)
Parameter Pre-
treatment
(median
scores)
Post-
treatment
(median
scores)
Wilcoxon
matched
pair test
(pZ)
Generic Instruments
SF36—physical
function
35.00 40.00 0.01
SF36—role
physical
25.00 25.00 0.14
SF36—bodily
pain
41.00 51.00 0.05
SF36—general 52.00 50.00 0.32
Disease-specific Quality of Life and Claudication 49Wilcoxon matched pair test), but similar improvement
was not seen in the VAS index (pZ0.30) (Table 3).
Although, the study mainly concentrated on the
validity of disease-specific QOL instruments, there
was good construct validity of the SF36 domains and
the two EUROQOL indices. This was suggested by
significant Spearman rank correlations between these
domains and indices and ICD and MWD (Spearman
rank correlation 0.219–0.576, p!0.05). Similar signifi-
cant correlations were not seen between the generic
domains and indices and ABPI.health
SF36—vitality 45.00 50.00 0.04
SF36—social
function
75.00 75.00 0.06
SF36—role
emotional
66.70 66.70 0.36
SF36—mental
health
72.00 76.00 0.05
EURO—TTO 0.66 0.69 0.02
EURO—VAS 62.5 68.0 0.30
Disease-specific instruments
CLAUS—
everyday life
52.78 61.11 0.01
CLAUS—pain 42.33 57.31 0.01
CLAUS—social
life
81.25 93.75 0.01
CLAUS—illness
sp. fears
76.92 86.54 0.01
CLAUS—psycho
well-being
81.82 85.23 0.02
VASCUQOL 4.08 5.16 0.01
SIPIC 6 4 0.05Disease-specific QOL instruments
Significant improvements were seen in all three
disease-specific QOL instruments after treatment.
The everyday life (EDL) domain of CLAUS improved
from a median score of 52.78 pre-treatment to a
median score of 61.11 post-treatment. CLAUS-pain
score improved from 42.33 to 57.31. Similar significant
improvements were also registered in the social life
(SL), illness-specific fears (ISF) and psychological well-
being (PW) domains of CLAUS post-treatment (p!
0.02, Wilcoxon matched pair test). The median
VASCUQOL score in the 70 claudicants was 4.08,
which increased to 5.16 post-treatment, a significant
improvement (pZ0.01). The median SIPIC score
dropped from 6 to 4 suggesting a significantly
improved QOL following treatment (pZ0.05 Wilcoxon
matched pair test). Table 3 shows the median QOL
scores for generic and disease-specific QOL instru-
ments pre and post treatment.Table 4. Construct validity
ICD MWD ABPI-R ABPI-PE
CLAUS
Everyday life 0.568** 0.614** 0.160 K0.1
Pain 0.677** 0.697** 0.100 K0.171
Social life 0.546** 0.559** 0.086 K0.177
Illness-specific fears 0.359** 0.438** 0.083 K0.064
Psychological
well being
0.267** 0.295** 0.013 K0.112
VASCUQOL 0.554** 0.637** 0.157 K0.136
SIPIC K0.466** K0.589** K0.114 0.170
**pZ0.01, Spearman rank order correlation).Validity
Validity was assessed using two methods i.e.
construct validity and convergent-divergent validity.
Significant Spearman rank order correlation between
all the five domains of the CLAUS and ICD (0.267–
0.677, p!0.05) and between CLAUS domains and
MWD (0.295–0.697, p!0.05) suggests a high degree
of ‘construct’ validity. Similarly, the VASCUQOL
and SIPIC also showed highly significant correlation
with both ICD and MWD (0.466–0.637, p!0.01)
suggesting that these questionnaires also possess
good construct validity. However, none of the
disease-specific domains or indices tested in this
study showed any correlation with the ABPI.
Table 4 demonstrates the good construct validity
of the CLAUS, VASCUQOL and SIPIC. Convergent
and divergent validity refers to correlation between
like domains of QOL instruments and, therefore,
applies to QOL profiles as apposed to QOL indices.Using the Spearman rank order correlation test, a
higher correlation was seen between like domains of
the CLAUS and SF36 (the two QOL profiles in this
study) as apposed to non-like domains suggesting
good ‘convergent’ and ‘divergent’ validity of the
CLAUS (Table 5).Responsiveness
Responsiveness of the QOL instruments was tested
using effect sizes. An effect size greater than 0.5 is
considered clinically significant. The ISCVS outcome
criteria were used to stratify the results followingEur J Vasc Endovasc Surg Vol 31, 1 2006
Table 5. Convergent and divergent validity
CLAUS—pain CLAUS—social life CLAUS—psychological well being
SF36—bodily pain 0.631** 0.642** 0.391**
SF36—social function 0.604** 0.802** 0.595**
SF36—mental health 0.214 0.469** 0.597**
Like domains show greater correlation than non-like domains. *p!0.05 and ** p!0.01, Spearman rank order correlation.
T. Mehta et al.50treatment. Six patients had a mild deterioration (K1),
16 patients had no change (0), 34 patients had mild
improvement (C1) and 14 patients had moderate
improvement (C2) following treatment as defined by
the ISCVS outcome criteria (Table 1). None of the
generic or disease-specific QOL questionnaires tested
here could detect mild deterioration in the 6 patients
with an ISCVS outcome of K1. The effect sizes for all
domain and questionnaires ranged from K0.24 to 0.83.
For a QOL instrument to detect this mild clinical
deterioration in patients, an effect size of at least K0.5
should be demonstrated to register a significant QOL
deterioration. In the 16 patients with no change (ISCVS
outcome 0), the effect sizes for all domains and
questionnaires ranged from K0.4 to 0.10, with none
greater than 0.5. As expected, since there was no
clinical difference in the patients’ condition after
treatment, none of the QOL instruments could register
a clinically significant difference in QOL in terms of
effect sizes. In the 34 patients with mild improvement
(ISCVS outcome C1), only the pain domain of CLAUS
(effect size 0.55) and the VASCUQOL (effect size 0.67)
could detect this mild improvement in terms of QOL
in a significant way. The remaining domains of
CLAUS, the SIPIC and all components of both generic
questionnaires had effect sizes !0.5 suggesting their
inability to detect any significant improvement in QOL
corresponding with improvement in the clinical
condition of the patient. Finally, in the 14 patients
with moderate improvement (ISCVS outcome C2),
three domains of the SF36 (physical function, bodily
pain and social function), VAS index of EUROQOL,
two domains of the CLAUS (everyday life and pain)Effect sizes
-0.6
-0.4
-0.2
0
0.2
0.4
0.6
0.8
1
-1 0 1 2
CLAUS-edl CLAUS-p VASC SIPic
Fig. 1. Responsiveness of disease-specific QOL instruments
using effect sizes for ISCVS outcomes: mild deterioration
(K1), no change (0), mild improvement (C1) and moderate
improvement (C2).
Eur J Vasc Endovasc Surg Vol 31, 1 2006and the VASCUQOL could detect a significant
improvement in QOL in terms of effect sizes (effect
size 0.5–0.74). The remaining domains and question-
naires were unable to register a clinically significant
effect size O0.5 even in this group with moderate
clinical improvement (Fig. 1).Discussion
CMT, supervised exercise programmes (SEP), PTA
and bypass surgery have all been advocated for the
treatment of IC. In this study, CMT and PTA were used
to treat 70 category II claudicants with reasonable
success. There was a significant improvement in all
clinical indicators of lower limb ischaemia i.e. walking
distances and ABPI after treatment. The patients
treated conservatively were given exercise advice,
which could explain the overall increase in walking
distances. Since, the majority of the patients were
treated with angioplasty (2/3rd), there was also an
overall increase in ABPI. According to ISCVS outcome
criteria, six patients deteriorated. This was due to
either a reduction in ABPI by 0.1 or more (three
patients) or inability to complete treadmill test (three
patients). Sixteen patients (23%) remained stable and
the majority, 48 out of 70 patients (69%), improved
after treatment. This suggests that current treatment
modalities for IC are reasonably effective.
The main aim of treating claudication is to reverse
its detrimental effect on QOL. Overall, the QOL
improved following treatment in our 70 patients.
Significant improvement in QOL (p!0.05, Wilcoxon
matched pair test) was seen only in four of the eight
domains of the SF36 (physical function, bodily pain,
vitality and mental health) and in the TTO index of the
EUROQOL, but not in the VAS index. On the contrary,
all domains and indices of all three disease-specific
QOL instruments studied, improved significantly after
treatment. This suggests that on the whole, disease-
specific QOL instruments may be more responsive
than generic QOL instruments.
Construct validity is the ability of a QOL instrument
to measure what it is supposed to measure.
A significant Spearman rank correlation between all
domains and indices of the disease-specific QOL
Disease-specific Quality of Life and Claudication 51instruments and treadmill walking distances suggests
that the three instruments have good construct
validity. For the CLAUS, although all five domains
showed statistically significant correlation with ICD
and MWD (p!0.05), the physical domains of everyday
life and pain had higher spearman correlation
coefficients (0.568–0.697) than the psychological
domains of illness specific fears and psychological
well-being (0.267–0.438). Not surprisingly, this
suggests a better correlation between physical
domains and treadmill walking distances as compared
to psychological domains.
For every disease-specific QOL domain and index
the spearman correlation coefficient was greater for
MWD than for ICD. For a claudicant, ICD represents
pain-free walking and the difference between MWD
and ICD is the painful walking that the claudicant
experiences. The magnitude of this difference between
ICD and MWD depends largely on the motivation and
pain threshold of the patient. Our results suggest that
it is MWD that is more important for the claudicant
and reduction in MWD has a more adverse impact on
the claudicants’ QOL.
There was no correlation between ABPI and
disease-specific QOL domains or indices. This
suggests that walking ability is more important for
the claudicant than total lower limb blood flow and a
reduction in walking ability has a much greater impact
on the claudicants’ QOL than a reduction in ABPI. This
also means that a lower ABPI does not equate with
poorer QOL and this factor alone should not be used to
plan or prioritise treatment in IC. The validity of
generic questionnaires has been established in IC8 and
this study aim to evaluate the validity of disease-
specific QOL instruments. However, our results show
that overall, the Spearman rank correlation coefficients
between disease-specific domains/indices and walk-
ing distances (0.267–0.697) was higher than the
correlation coefficients between generic domains/
indices and walking distances (0.219–0.576). This
suggests a better construct validity of the disease-
specific QOL instruments as compared with generic
QOL instruments.
The advantage of disease-specific QOL instruments
over generic QOL instruments is their greater respon-
siveness. This responsiveness should be equally
sensitive to improvement and deterioration in the
patients’ condition. However, none of the QOL
instruments studied here could detect mild deterio-
ration in the patients’ clinical condition in terms of
significant deterioration in QOL. Using effect sizes as a
measure of responsiveness, a significant deterioration
in QOL should register an effect size of K0.5. This was
not seen in any of the QOL instruments studied. Onereason for this could be a type II error or small
numbers, as only six patients had mild deterioration
(ISCVS outcome K1) following treatment. Another
reason often cited for poor responsiveness of QOL
instruments to deterioration is a ‘floor effect’ i.e.
patients initially score the lowest possible score so
further deterioration cannot be registered. This is
unlikely to be the case here because this study
involved claudicants, who unlike patients with critical
ischaemia are not clinically on the lowest rung of the
peripheral arterial disease ladder.
Sixteen claudicants in the study remained stable
with no change in their clinical condition following
treatment (ISCVS outcome 0). There was no significant
change in QOL in these patients as the effect size did
not reach the significant level of 0.5 for any of the
domains or indices. This is important because it
implies that there is no placebo effect associated with
QOL analysis.
Thirty-four claudicants had mild improvement
following treatment (ISCVS outcome C1). However,
only the pain domain of CLAUS and VASCUQOL
could detect this improvement in terms of significant
improvement in QOL. The stratification of clinical
outcome following treatment into mild, moderate and
marked as described by the ISCVS is based on a
combination of completion of treadmill walking test
and/or increase in ABPI and a reasonably responsive
QOL instrument should be able to detect improvement
in QOL in these three broad outcome categories
preferably in a step-wise fashion.
Fourteen claudicants had moderate improvement
following treatment (ISCVS outcome C2). Only two
domains of CLAUS (pain and everyday life) and
VASCUQOL demonstrated significant improvement
in QOL in these patients. For the CLAUS this seems
disappointing, being a disease-specific QOL instru-
ment specifically designed for IC, one may expect
significant QOL improvements in all its five domains
in this group of moderate clinical improvement. Three
of the eight domains of SF36 were able to detect
moderate clinical improvement in terms of significant
improvement in QOL. In terms of responsiveness, the
SF36 appears to be equivalent to the CLAUS. The SF36
is the established generic QOL instrument for IC, but
the extra time, effort and resources involved in
administering the CLAUS along with the SF36 could
be questioned.
In conclusion, validity, both construct and con-
vergent-divergent validity is acceptable for all three
disease-specific QOL instruments tested. The VASCU-
QOL was the only instrument that could detect both
mild and moderate clinical improvement and thus
offers advantages over generic QOL indices. We,Eur J Vasc Endovasc Surg Vol 31, 1 2006
T. Mehta et al.52therefore, recommend, based on responsiveness,
the VASCUQOL is the only disease-specific QOL
instrument that merits routine use in claudicants.
The SF36 is the established leader amongst generic
QOL instruments. Therefore, future researchers and
clinicians analysing QOL in claudicants should
include the generic questionnaire SF36 and the
disease-specific questionnaire VASCUQOL.References
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